key: cord-0926718-jubae9sb
authors: Kwiatkowski, Shaina; Mulugeta, Surafel; Davis, Susan; Kenney, Rachel; Kalus, James; Walton, Leslie; Patel, Nisha
title: Optimizing preoperative antibiotics in patients with β-lactam allergies: A role for pharmacy
date: 2021-05-26
journal: Am J Health Syst Pharm
DOI: 10.1093/ajhp/zxab218
sha: 2365c7ccfbdec434768469bb319effd504500c88
doc_id: 926718
cord_uid: jubae9sb

DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: Patients with a reported β-lactam allergy (BLA) are often given alternative perioperative antibiotic prophylaxis, increasing risk of surgical site infections (SSIs), acute kidney injury (AKI), and Clostridioides difficile infection (CDI). The purpose of this study was to implement and evaluate a pharmacist-led BLA clarification interview service in the preoperative setting. METHODS: A pharmacist performed BLA clarification telephone interviews before elective procedures from November 2018 to March 2019. On the basis of allergy history and a decision algorithm, first-line preoperative antibiotics, alternative antibiotics, or allergy testing referral was recommended. The pharmacist intervention (PI) group was compared to a standard of care (SOC) group who underwent surgery from November 2017 to March 2018. RESULTS: Eighty-seven patients were included, with 50 (57%) and 37 (43%) in the SOC and PI groups, respectively. The most common surgeries included orthopedic surgery in 41 patients (47%) and neurosurgery in 17 patients (20%). In the PI group, all BLA labels were updated after interview. Twenty-three patients were referred for allergy testing, 12 of the 23 (52%) completed BLA testing, and penicillin allergies were removed for 9 of the 12 patients. Overall, 28 of the 37 (76%) pharmacy antibiotic recommendations were accepted. Cefazolin use significantly increased from 28% to 65% after the intervention (P = 0.001). SSI occurred in 5 (10%) patients in the SOC group and no patients in the PI group (P = 0.051). All of these SSIs were associated with alternative antibiotics. Incidence of AKI and CDI was similar between the groups. No allergic reactions occurred in either group. CONCLUSION: Implementation of a pharmacy-driven BLA reconciliation significantly increased β-lactam preoperative use without negative safety outcomes.

M a n u s c r i p t 4 Penicillin allergies are reported in 10% of the general population; however, 90% to 99% of these patients can safely receive -lactams. 1 First-line antibiotics for surgical infection prophylaxis include cefazolin or cefoxitin, but patients with a reported -lactam allergy (BLA) are more likely to receive alternative antibiotics such as vancomycin, clindamycin, or gentamicin. 2, 3 These alternatives increase the risk of Clostridioides difficile infection (CDI) and acute kidney injury (AKI) and the potential to develop antibiotic resistance. 3 One study demonstrated that patients with reported penicillin allergies had 50% increased odds of developing a surgical site infection (SSI), attributable to receiving alternative antimicrobial prophylaxis. 3 SSIs are associated with short-and long-term patient harm such as rehospitalization, prolongment of hospital length of stay (LOS) by 7 to 10 days, and lower quality of life, infection-related complications, a mortality rate of 3%, and an estimated cost of over $25,000 and penalties in procedure reimbursement. [4] [5] [6] National guidelines recommend clarifying all BLAs, but many are unclarified before giving alternative antibiotics in the perioperative setting. 2 Previous studies have described successful allergy interventions such as BLA interviews, cross-reactivity charts, -lactam skin testing, and oral -lactam antibiotic challenge in the preoperative setting. [7] [8] [9] [10] These studies showed significant increases in -lactam antibiotic prophylaxis use and operating room time saved when the prolonged infusion time of vancomycin was avoided.

Pharmacists are well trained and positioned to optimize preoperative antibiotic selection to potentially decrease intraoperative time, adverse effects, and risk of SSI. The purpose of this study was to implement and evaluate a pharmacist-led BLA interview to optimize surgical infection prophylaxis.

A c c e p t e d M a n u s c r i p t 5 This was a single-center, quasi-experimental   study at a large academic medical center with about 1,200 elective surgical cases performed monthly. Select patients meeting criteria were seen at our institution's perioperative optimization clinic for clearance about 2 to 3 weeks before surgery. These patients included higher-risk patients such as those who had a recent ST-elevation myocardial infarction or cardiovascular event, patients on home oxygen, patients with end-stage renal disease or end-stage liver disease, and patients who were fully dependent. In addition, patients Patients were included if they had a BLA, a perioperative optimization clinic appointment, and a surgery where a -lactam antibiotic was considered first for SSI prophylaxis. 11 Exclusion criteria included non-English speakers, pregnancy, and transplant surgery. The study was approved by the institution's investigational review board with waiver of consent.

Intervention. Before implementation, pharmacy met with key stakeholders from infectious disease, surgery, anesthesiology, and allergy for input and approval of all The interview reviewed the reaction, timing, and tolerance of other -lactam antibiotics (Appendix A). On the basis of allergy history and the decision algorithm, first-line antibiotics, alternative antibiotics, or an electronic allergy testing referral was recommended and documented in the electronic medical record (EMR) (Figure 1 ). Antibiotic recommendations followed institutional guidelines, which are consistent with national surgical infection prophylaxis guidelines. 3 Vancomycin was added to regimens if the patient had institution-specified methicillin-resistant Staphylococcus aureus (MRSA) risk factors. 11 The allergy label in the EMR was updated with details discussed during the interview Endpoints. The primary endpoint was the use of -lactams preoperatively.

Secondary endpoints included clinical outcomes and process measures. Clinical outcomes included 30-day SSI and CDI, AKI, allergic reactions, and LOS. SSI was defined according to the Centers for Disease Control and Prevention definitions at day 30 after surgery. 10 CDI was defined as presence of diarrhea and either a positive stool test result for the presence of C. difficile or its toxins or colonoscopic or histopathologic findings of pseudomembranous A c c e p t e d M a n u s c r i p t 7 colitis. 13 Allergic reaction was defined as a type I hypersensitivity reaction, cytotoxic reaction, serum sickness, drug reaction with eosinophilia and systemic symptoms, severe cutaneous adverse reaction, or toxic epidermal necrolysis within 7 days of preoperative antibiotic administration. AKI was defined as an increase in serum creatinine levels of 0.3 mg/dL or serum creatinine levels greater than 1.5 times baseline within 4 days of preoperative antibiotic administration. 14 LOS was defined as the time from the day of surgery to the day of discharge. Process outcomes included allergy labels updated or removed, recommendations accepted by the physician, vancomycin doses administered, and time to incision. Time to incision was defined as the time from operating room entry to the first incision. 8 A nonequivalent dependent variable, sequential compression device order, was used to potentially control for maturation bias between the 2 study time periods.

Analysis. Continuous variables were compared using Mann-Whitney tests or t tests, as appropriate. Categorical data were compared using  2 tests. It was estimated that 46 individuals were needed per group for an effect size of 26% reduction in alternative antibiotics to meet 80% power and a 2-sided  value of 0.05. 7 Data analysis was performed using SPSS, version 22.0 (IBM Corporation, Armonk, NY).

Overall, 129 patients were screened for inclusion: 74 patients in the SOC group and 55 patients in the PI group. Fifty patients were included in the SOC group, and 37 patients were included in the PI group. The most common reason for exclusion in the SOC group and PI group was patients not having elective surgery (n = 10, 14%) and patients unable to be reached by telephone after 3 attempts (n = 13, 24%), respectively. Patient demographics and reported allergy characteristics are described in A c c e p t e d M a n u s c r i p t 8 Table 1 . There were significantly more patients undergoing orthopedic surgery and neurosurgery in the PI group than in the SOC group. The SOC group had a greater variety of surgeries as compared to the PI group, including vascular, bariatric, and gynecologic surgeries. Allergy characteristics were similar between the groups. The most common reported allergen was penicillin (66% vs 61% in the SOC and PI groups, respectively). The most common patient-reported drug reactions were rash (34% vs 18%), unknown reaction (22% vs 21%), and multiple reactions (20% vs 21%) in the 2 groups.

Postintervention allergy outcomes and recommendations. All 37 patients in the PI group had allergy labels updated, and 23 of them (64%) were referred to an allergy clinic for testing. Of the patients who were referred, 13 (57%) followed up with an allergy clinic a median of 7 days (interquartile range [IQR], 4-9 days) after the telephone call. The allergy appointment occurred a median of 14 days (IQR, 13-16 days) before the day of surgery. Of these patients, 9 (69%) passed the penicillin allergy test, 3 (23%) failed testing, and 1 (8%) did not receive testing due to the patient's decision to defer allergy testing. Patients who passed the penicillin allergy test had the penicillin allergy label removed by an allergist. Of note, 2 patients had both a penicillin and cephalosporin allergy, so only the penicillin allergy label was removed after passing the allergy test while the cephalosporin allergy label remained on the chart. Preoperative antibiotics and outcomes. Cefazolin use significantly increased from 28% (14/50) to 65% (24/37) after the intervention (P = 0.001; Table 2 ). The most common preoperative regimen in the SOC group was clindamycin plus gentamicin (14/50). In the PI group, cefazolin (12/37) and cefazolin plus vancomycin (12/37) were used most commonly.

Overall, vancomycin use increased from use in 19 patients (38%) to use in 22 patients (59%) (P = 0.047). Vancomycin monotherapy or vancomycin in combination with alternative antibiotics was used in 14 (28%) and 10 (27%) patients in the SOC and PI groups, respectively. Vancomycin was added to cefazolin due to presence of a MRSA risk factor in 5 (10%) and 12 (32%) patients in the SOC and PI groups. Overall, time to incision decreased by a median of 8 minutes (P = 0.484).

No SSIs occurred in the PI group. In the SOC group, 5 (10%) SSIs occurred (P = 0.051), and all were associated with alternative antibiotic use. AKI occurred in 2 (4%) patients who received alternative antibiotics preoperatively in the SOC group. No AKI occurred in the PI group. One instance of CDI occurred in a patient who received clindamycin plus gentamicin in the SOC group, while there was no incidence of CDI in the PI group. No allergic reactions occurred in either group. The LOS was a median of 2 days in each group with an IQR of 2.0 to 4.5 days and 2.0 to 2.0 days in the SOC and PI groups, respectively (P = 0.014). The nonequivalent dependent variable of sequential compression device order was similar between the groups (96% vs 97%, P = 0.761).

BLA evaluation before surgery led to an increase in first-line -lactam antibiotic use without negative safety outcomes. The harms of reported BLA have been well described in the literature and include increased odds of SSI, AKI, and CDI. 3, 4 Although this study had a smaller sample size, the study showed similar trends in higher SSI, AKI, and CDI with A c c e p t e d M a n u s c r i p t 10 alternative antibiotic use perioperatively. Notably, LOS was significantly different because there was a wider range of days of hospitalization in the SOC group than in the PI group. The success of the intervention relied on collaboration among the key stakeholders in the surgical process: pharmacy, infectious disease, surgery, and allergy leadership.

This study adds to the growing body of literature describing BLA clarification interventions in the preoperative setting. One of the challenges of BLA clarification is the lack of ownership of the allergy label. In previous literature, various disciplines have been described as taking responsibility for the BLA clarification process, including pharmacy, nurses, allergists, and infectious disease physicians. 7, 8 Pharmacists are well equipped to perform BLA clarification interviews and assess BLA in relation to cross-reactivity of lactams, severity of reaction, and prior antibiotic use. This study highlights the importance of the pharmacist's role in BLA clarification interviews and describes another service for pharmacy.

Although this study utilized a pharmacist to carry out the intervention, we recognize a potential role for pharmacy technicians and student pharmacists in this area. Previous studies successfully trained medication history pharmacy technicians and student pharmacists to conduct allergy histories. [15] [16] [17] There are several limitations to the study. First, there was a limited time to follow-up of 30 days after surgery, so it is possible that some clinical outcomes were unaccounted for after the 30-day time point. Also, maturation bias, use of a historical control group, and lack of randomization are limitations inherent to a quasi-experimental study. To control for this, the study periods were chosen to correspond to the same time period during the year and a nonequivalent dependent variable (sequential compression device) was used to assess for prescribing practice changes for a similar quality measure, which nearly all patients Cefazolin administered

Cefazolin recommended (n=19) 89% 11%

Alternative antibiotics recommended (n=18) 39% 61%

Joint Task Force on Practice Parameters

American College of Allergy, Asthma, and Immunology; Joint Council of Allergy, Asthma, and Immunology. Drug allergy: an updated practice parameter

Clinical practice guidelines for antimicrobial prophylaxis in surgery

The impact of a reported penicillin allergy on surgical site infection risk

Misconceptions surrounding penicillin allergy: implications for anesthesiologists

Association of postoperative infection with risk of long-term infection and mortality

Severity and long-term complications of surgical site infections after orthognathic surgery: a retrospective study

Optimizing preoperative prophylaxis in patients with reported -lactam allergy: a novel extension of antimicrobial stewardship

De-labeling of -lactam allergy reduces intraoperative time and optimizes choice in antibiotic prophylaxis

Impact of an antibiotic side chain-based crossreactivity chart combined with enhanced allergy assessment processes for surgical 2021

Screening for -lactam allergy in joint arthroplasty patients to improve surgical prophylaxis practice

Henry Ford Health System Tier 1: Surgical Infection Prophylaxis in Adult Elective Surgery Policy. Henry Ford Health System

Surgical Site Infection Event (SSI). National Healthcare Safety Network

Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

KDIGO clinical practice guidelines for acute kidney injury

Confronting the challenge of -lactam allergies: a quasiexperimental study assessing impact of pharmacy-led interventions

Impact of a standardized -lactam allergy questionnaire on aztreonam use

The authors thank Edward Zoratti, MD, for his assistance with the implementation of the intervention and continued support throughout the study.

Dr. Davis reports receiving honoraria for consulting from Allergan plc, Spero, and Tetraphase, unrelated to the submitted work. The authors have declared no potential conflicts of interest.

At the time of the described work, Dr. Kwiatkowski was in the Department of Pharmacy Services, Henry Ford Hospital, Detroit, MI.

A c c e p t e d M a n u s c r i p t M a n u s c r i p t